Blood Group Lewis y Antibody [A70-A/A9] | 33-676

Blood Group Lewis y Antibody [A70-A/A9] | 33-676 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Live Ls174T cells (human colon carcinoma) were used as the immunogen for the Lewis y antibody.

Research Area: Other

Tested Application: Flow, IF, IHC-P

Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE) : 0.5-1 ug/ml for 30 min at RT
Optimal dilution of the Lewis y antibody should be determined by the researcher.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: A70-A/A9

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: N/A

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: This antibody recognizes a carbohydrate epitope present on tumor-associated Lewis y antigen (Fucalpha1-2Galbeta1-4/3[Fucalpha1-3/4]GlcNAcbeta-) . Lewis y is expressed in large bowel tumors and colorectal carcinomas. It may be useful in the classification of human renal and bladder tumors. The Lewis y antigen has been evaluated as a clinical marker for the diagnosis and prognosis of cholangiocarcinoma, hepatocellular carcinoma and breast cancer.